MEK inhibitors: a patent review 2008 – 2010
Author:
Publisher
Informa Healthcare
Subject
Drug Discovery,Pharmacology,General Medicine
Link
http://www.tandfonline.com/doi/pdf/10.1517/13543776.2011.577068
Reference29 articles.
1. Emerging MEK inhibitors
2. Recent Developments in Anti-Cancer Agents Targeting the Ras/Raf/ MEK/ERK Pathway
3. Putative allosteric MEK1 and MEK2 inhibitors
4. Recent Advances of MEK Inhibitors and Their Clinical Progress
5. Progress Towards Therapeutic Small Molecule MEK Inhibitors for Use in Cancer Therapy
Cited by 36 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies;Signal Transduction and Targeted Therapy;2023-12-18
2. Current Market Potential and Prospects of Copper-based Pyridine Derivatives: A Review;Current Molecular Medicine;2023-07-26
3. Discovery of carbazole derivatives as novel allosteric MEK inhibitors by pharmacophore modeling and virtual screening;European Journal of Medicinal Chemistry;2019-09
4. Discovery of EBI-1051: A novel and orally efficacious MEK inhibitor with benzofuran scaffold;Bioorganic & Medicinal Chemistry;2018-02
5. MEK inhibitors in oncology: a patent review (2015-Present);Expert Opinion on Therapeutic Patents;2017-06-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3